NCT01885299
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: Child, Adult, Older Adult
Location of Metastases: Brain
Additional Notes: Patients must have brain tumors treatable by stereotactic radiosurgery or stereotactic body radiotherapy
Exclusions: 
https://ClinicalTrials.gov/show/NCT01885299